The firm reported on Tuesday that its diagnostics revenues rose 6 percent from a year ago while its biopharma lab services revenues rose almost 2 percent.

The firm said that its overall revenues rose 2 percent year over year and 4 percent on an organic basis with a smaller increase in its life sciences revenues.

The real-time PCR-based companion diagnostic test identifies patients eligible for treatment with Amgen's Vectibix (panitumumab).

NEW YORK — Digital pathology firm Gestalt Diagnostics said on Monday that it has raised $7.5 million through a Series A financing round. The round was led by Cowles Ventures, TVF Funds, Inland Imaging ...

The first $25 million tranche was funded at close and used to retire Exagen's existing term debt facility with Innovatus Capital Partners.

Last week, readers were most interested in a story about Akoya's collaboration to identify markers predictive of response to checkpoint inhibitor therapy.

The company said during a conference call following release of its Q1 2025 results that it purchases roughly 80 percent of ...

In one case a firm is alleged to have improperly billed the COVID-19 Uninsured Program while in the other a firm paid and received kickbacks for unnecessary genetic testing.

The company, also known as DRW, shared early data on its forthcoming multiplex qPCR-based platform and infectious disease ...

SSID Group said that the assets acquired in the deal will complement its gastric health portfolio and let it offer a broader range of tests to US labs.

NEW YORK — Swiss healthcare firm Roche said Monday that it intends to invest $50 billion over the next five years into expanding its footprint in the US. According to Roche, the money will be used in ...

Note: This story has been updated with comments from Roche's conference call to discuss its financial results. NEW YORK – Impacts from China's volume-based procurement program and other healthcare ...